We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why This Cheap Gaming-Focused Stock is a Strong Buy Right Now
Read MoreHide Full Article
Everi Holdings Inc. (EVRI - Free Report) provides technology for the casino industry, from gaming machines to fintech. EVRI shares have soared 80% in the last year but they are still cheap. Plus, Everi’s outlook appears strong heading into its fourth quarter 2019 earnings release and beyond.
The Everi Basics
Everi is a Las Vegas-based casino tech firm that offers a variety of gaming machines, services, and more. The company also sells financial services-focused products, player loyalty offerings, as well as intelligence and regulatory compliance solutions.
EVRI topped our Q3 earnings and revenue estimates back in November, with its Games and FinTech units helping drive its 12% top-line growth. Meanwhile, its quarterly earnings jumped from $0.03 in the year-ago period to $0.12 a share. And last quarter marked Everi’s 13th consecutive quarter of year-over-year revenue and Adjusted EBITDA expansion.
Investors should also note that the firm announced in mid-January that it extended its relationship with the New York Lottery for 10 more years. EVRI’s central system currently monitors and administers more than 17,000 Video Lottery Terminals across nine facilities in the state.
Other Fundamentals
Last quarter, Everi generated free cash flow of $11 million to push its total up to $39.3 million on the year. This strong cash generation has helped the company reduce its debt load.
The nearby chart, meanwhile, shows us just how impressive of a run EVRI stock has been on since the summer of 2016. EVRI stock was trading at roughly $1 per share in June 2016 and it currently hovers at around $13.60 per share.
Despite this run, Everi holds an “A” grade for Value in our Style Scores system, alongside an “A” for Growth. We can also see that its longer-term earnings revisions have trended heavily upward, especially for fiscal 2020 and 2021.
Outlook
Looking ahead, our current Zacks estimates call for Everi’s fourth quarter revenue to jump 11.6% to $133.3 million that would see it roughly match Q3’s growth. Meanwhile, its fiscal 2019 revenue is projected to pop over 11% to $521.4 million. The company’s 2020 sales are then expected to climb another 9.2% higher to $569.1 million.
At the bottom end of the income statement, Everi’s adjusted Q4 earnings are expected to skyrocket from a loss of -$0.04 per share in the year-ago period to +$0.08.
Overall, its fiscal 2019 EPS figure is projected to soar 250% from $0.10 to $0.35 a share. And in a sign of continued expansion, EVRI’s 2020 earnings are expected to reach $0.58, which would mark another 65% climb.
Bottom Line
Everi’s solid earnings estimate revisions activity helps it earn a Zacks Rank #1 (Strong Buy) at the moment. The stock also rocks an overall “A” VGM grade, with it set to report its Q4 results on March 2. And some investors might be attracted to its “cheap” price of well under $20 a share.
In the end, Everi appears to be a stock worth considering given its growth outlook, within a gaming-focused space that includes other highly-ranked stocks such as MGM Resorts International (MGM - Free Report) , Churchill Downs (CHDN - Free Report) , and fellow low-priced SciPlay Corporation . And let’s not forget that U.S. unemployment remains low and indexes rest right near their new highs despite coronavirus fears.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Why This Cheap Gaming-Focused Stock is a Strong Buy Right Now
Everi Holdings Inc. (EVRI - Free Report) provides technology for the casino industry, from gaming machines to fintech. EVRI shares have soared 80% in the last year but they are still cheap. Plus, Everi’s outlook appears strong heading into its fourth quarter 2019 earnings release and beyond.
The Everi Basics
Everi is a Las Vegas-based casino tech firm that offers a variety of gaming machines, services, and more. The company also sells financial services-focused products, player loyalty offerings, as well as intelligence and regulatory compliance solutions.
EVRI topped our Q3 earnings and revenue estimates back in November, with its Games and FinTech units helping drive its 12% top-line growth. Meanwhile, its quarterly earnings jumped from $0.03 in the year-ago period to $0.12 a share. And last quarter marked Everi’s 13th consecutive quarter of year-over-year revenue and Adjusted EBITDA expansion.
Investors should also note that the firm announced in mid-January that it extended its relationship with the New York Lottery for 10 more years. EVRI’s central system currently monitors and administers more than 17,000 Video Lottery Terminals across nine facilities in the state.
Other Fundamentals
Last quarter, Everi generated free cash flow of $11 million to push its total up to $39.3 million on the year. This strong cash generation has helped the company reduce its debt load.
The nearby chart, meanwhile, shows us just how impressive of a run EVRI stock has been on since the summer of 2016. EVRI stock was trading at roughly $1 per share in June 2016 and it currently hovers at around $13.60 per share.
Despite this run, Everi holds an “A” grade for Value in our Style Scores system, alongside an “A” for Growth. We can also see that its longer-term earnings revisions have trended heavily upward, especially for fiscal 2020 and 2021.
Outlook
Looking ahead, our current Zacks estimates call for Everi’s fourth quarter revenue to jump 11.6% to $133.3 million that would see it roughly match Q3’s growth. Meanwhile, its fiscal 2019 revenue is projected to pop over 11% to $521.4 million. The company’s 2020 sales are then expected to climb another 9.2% higher to $569.1 million.
At the bottom end of the income statement, Everi’s adjusted Q4 earnings are expected to skyrocket from a loss of -$0.04 per share in the year-ago period to +$0.08.
Overall, its fiscal 2019 EPS figure is projected to soar 250% from $0.10 to $0.35 a share. And in a sign of continued expansion, EVRI’s 2020 earnings are expected to reach $0.58, which would mark another 65% climb.
Bottom Line
Everi’s solid earnings estimate revisions activity helps it earn a Zacks Rank #1 (Strong Buy) at the moment. The stock also rocks an overall “A” VGM grade, with it set to report its Q4 results on March 2. And some investors might be attracted to its “cheap” price of well under $20 a share.
In the end, Everi appears to be a stock worth considering given its growth outlook, within a gaming-focused space that includes other highly-ranked stocks such as MGM Resorts International (MGM - Free Report) , Churchill Downs (CHDN - Free Report) , and fellow low-priced SciPlay Corporation . And let’s not forget that U.S. unemployment remains low and indexes rest right near their new highs despite coronavirus fears.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>